BioStem Technologies, Inc.: stock overview

BSEMNASDAQHealthcare · Biological Products, (No Diagnostic Substances)New listingsince Aug 6, 2026

Price

$1.05

November 13, 2026Market cap $20M

New listing: quarterly reports only so far

The first annual report (10-K) is expected around March 31, 2027; valuation and multi-year figures start then.

In short

BioStem Technologies has been listed since August 6, 2026. In the quarter to September 30, 2026 it reported revenue of $7.6M and a net loss of $11M. Revenue was 27.0% below the same quarter a year earlier ($10M). On September 30, 2026 it held $971.1K of cash and $1.0M of debt.

Figures from the quarterly reports (10-Q) to the quarter ended September 30, 2026; price as of November 13, 2026.

Latest 10-Q

Market cap: $20M; 19.18M shares
Revenue, quarter: $7.6M; to Sep 30, 2026
Net income, quarter: -$11M; to Sep 30, 2026
Cash: $971.1K; on Sep 30, 2026

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

The quarters it has reported

Each quarter as its 10-Q reports it, beside the same quarter a year earlier, which the same report gives for comparison.

2 quarters

Q3 2026to Sep 30, 2026
Change-27.0%
Q2 2026to Jun 30, 2026
Change-27.9%

Quarter	Revenue	Change	Net income	EPS (diluted)	Filing
Q3 2026to Sep 30, 2026	$7.6Ma year earlier: $10M	-27.0%	-$11Ma year earlier: $761.1K	-$0.64a year earlier: $0.03	10-Q
Q2 2026to Jun 30, 2026	$7.9Ma year earlier: $11M	-27.9%	-$9.0Ma year earlier: $10.6K	-$0.52a year earlier: $0.00	10-Q

Earnings per share for quarters before the listing divide by the fewer shares there were then, so they do not compare directly with today's.

Balance sheet

From the latest 10-Q, beside the end of the previous fiscal year, which the same report gives for comparison.

Line	Sep 30, 2026	Dec 31, 2025
Total assets	$44M	$50M
Cash and equivalents	$971.1K	$30M
Total debt	$1.0M	$3.0M
Shareholders' equity	$18M	$39M

The company at the SEC

How it is registered and when its fiscal year ends.

Listing: Exchange certification of the listing (CERT), August 6, 2026
Latest quarterly report: 10-Q for the quarter to September 30, 2026
First annual report: around March 31, 2027
Name at the SEC: BioStem Technologies, Inc.
CIK: 1658678
Exchange: NASDAQ
Industry (SIC): 2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Shares: 19.18M, 10-Q cover, Nov 11, 2026

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.